Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Gabapentin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL7047893 | 0.98 | CYP1A2 (0.92) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6544499 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL466183 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL179836 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 0.98 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL19031792 | 0.96 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6689206 | 0.96 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL26730 | 0.96 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6672099 | 0.96 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636172-B1 | PROCESS FOR THE PURIFICATION OF GABAPENTIN | ZACH SYSTEM SPA (IT) | 2012-08-22 | — | — | EP | claimed |
| US-7393975-B2 | Process for the purification of gabapentin | ZACH SYSTEM S.P.A. (IT) | 2008-07-01 | — | — | US | claimed |
| US-20070129569-A1 | Process for the purification of gabapentin | ZAMBON GROUP S.P.A. (IT) | 2007-06-07 | — | — | US | claimed |
| EP-1636172-A1 | PROCESS FOR THE PURIFICATION OF GABAPENTIN | ZAMBON GROUP S.p.A. (IT) | 2006-03-22 | — | — | EP | claimed |
| EP-1494996-A1 | PROCESS FOR PREPARING GABAPENTIN | Taro Pharmaceutical Industries Limited (IL) | 2005-01-12 | — | — | EP | claimed |
| WO-2004113269-A1 | PROCESS FOR THE PURIFICATION OF GABAPENTIN | ZAMBON GROUP SPA (IT) | 2004-12-29 | — | — | WO | claimed |
| US-20040034248-A1 | Process for preparing gabapentin | TARO PHARMACEUTICAL INDUSTRIES, LTD. | 2004-02-19 | — | — | US | claimed |
| WO-2003089403-A1 | PROCESS FOR PREPARING GABAPENTIN | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-10-30 | — | — | WO | claimed |
| CN-115697315-B | Co-crystals of gabapentin, ketoprofen and lysine, pharmaceutical composition and medical application thereof | 东佩制药股份公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230357121-A1 | CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-11-09 | — | — | US | disclosed |
| US-20230181507-A1 | CO-CRYSTAL OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-06-15 | — | — | US | disclosed |
| US-20230165820-A1 | SYNERGISTIC ADMIXTURES OF GABAPENTIN AND KETOPROFEN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2023-06-01 | — | — | US | disclosed |
| WO-2023072908-A1 | CO-CRYSTALS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | DOMPE' FARMACEUTICI SPA (IT) | 2023-05-04 | — | — | WO | disclosed |
| EP-4169903-A1 | CO-CRYSTALS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | Dompe' Farmaceutici S.P.A. (IT) | 2023-04-26 | — | — | EP | disclosed |
| EP-1694632-A1 | PROCESS FOR THE PURIFICATION OF GABAPENTIN | ZAMBON GROUP S.p.A. (IT) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005092837-A2 | PROCESS FOR THE PREPARATION OF GABAPENTIN | ZAMBON GROUP S.P.A. (IT) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005058797-A1 | PROCESS FOR THE PURIFICATION OF GABAPENTIN | ZAMBON GROUP S.P.A. (IT) | 2005-06-30 | — | — | WO | disclosed |
| EP-1494996-A1 | PROCESS FOR PREPARING GABAPENTIN | Taro Pharmaceutical Industries Limited (IL) | 2005-01-12 | — | — | EP | disclosed |
| US-20040034248-A1 | Process for preparing gabapentin | TARO PHARMACEUTICAL INDUSTRIES, LTD. | 2004-02-19 | — | — | US | disclosed |
| WO-2003089403-A1 | PROCESS FOR PREPARING GABAPENTIN | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034248-A1 | Process for preparing gabapentin | GABRP, GABRD, SLC6A13 | CACNA2D1 483/4885CYP1A2 1930/4885ALDH1A1 886/4885 |
| US-20230181507-A1 | CO-CRYSTAL OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | GABARAP, GABRA5, GABARAPL1 | CACNA2D1 426/4885CYP1A2 1282/4885ALDH1A1 2009/4885 |
| US-20230165820-A1 | SYNERGISTIC ADMIXTURES OF GABAPENTIN AND KETOPROFEN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | OPRK1, KCNQ5, KCNQ3 | CACNA2D1 269/4885CYP1A2 674/4885ALDH1A1 369/4885 |
| US-20230357121-A1 | CO-CRYSTAL OF KETOPROFEN, LYSINE AND GABAPENTIN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | GABARAP, GABRA5, KMO | CACNA2D1 485/4885CYP1A2 1024/4885ALDH1A1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.